Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: What next?

Carol Hopkins Sibley, John E. Hyde, Paul F G Sims, Christopher V. Plowe, James G. Kublin, Edward K. Mberu, Alan F. Cowman, Peter A. Winstanley, William M. Watkins, Alexis M. Nzila

    Research output: Contribution to journalArticlepeer-review


    Chemotherapy remains the only practicable tool to control falciparum malaria in sub-Saharan Africa, where >90% of the world's burden of malaria mortality and morbidity occurs. Resistance is rapidly eroding the efficacy of chloroquine, and the combination pyrimethamine-sulfadoxine is the most commonly chosen alternative. Resistant populations of Plasmodium falciparum were selected extremely rapidly in Southeast Asia and South America. If this happens in sub-Saharan Africa, it will be a public health disaster because no inexpensive alternative is currently available. This article reviews the molecular mechanisms of this resistance and discusses how to extend the therapeutic life of antifolate drugs.
    Original languageEnglish
    Pages (from-to)582-588
    Number of pages6
    JournalTrends in parasitology
    Issue number12
    Publication statusPublished - 1 Dec 2001


    Dive into the research topics of 'Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: What next?'. Together they form a unique fingerprint.

    Cite this